MX2017000544A - Compuestos de quinoxalina, metodo para preparar los mismos y uso de los mismos. - Google Patents
Compuestos de quinoxalina, metodo para preparar los mismos y uso de los mismos.Info
- Publication number
- MX2017000544A MX2017000544A MX2017000544A MX2017000544A MX2017000544A MX 2017000544 A MX2017000544 A MX 2017000544A MX 2017000544 A MX2017000544 A MX 2017000544A MX 2017000544 A MX2017000544 A MX 2017000544A MX 2017000544 A MX2017000544 A MX 2017000544A
- Authority
- MX
- Mexico
- Prior art keywords
- formula
- compounds
- themselves
- preparing
- same
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical class N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000002028 Biomass Substances 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000011065 in-situ storage Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 238000002203 pretreatment Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000000926 separation method Methods 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se describe un modulo de separacion de solidos/fluido y aparato y metodo de pre-tratamiento que permiten el pretratamiento de biomasa a alta temperatura y presion con la habilidad de hacer variar los tiempos de residencia y procesamiento. (Ver formula) en donde L es NR8 u O; R1, R2, R3, R4, R5, R6 y R7 se definen en la presente. Los compuestos de la formula (I) son utiles para la inhibicion de proteina cinasas. Se describen metodos para usar los compuestos de la formula (I), estereoisomeros, tautomeros y sales farmaceuticamente aceptables de los mismos, para diagnosis in vitro, in situ, e in vivo, prevencion o tratamiento de estos trastornos en celulas mamiferas, o condiciones patologicas asociadas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462025212P | 2014-07-16 | 2014-07-16 | |
| PCT/US2015/035822 WO2016010662A1 (en) | 2014-07-16 | 2015-06-15 | Quinoxaline compounds, method for preparing the same and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017000544A true MX2017000544A (es) | 2017-03-08 |
| MX385110B MX385110B (es) | 2025-03-11 |
Family
ID=55078907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017000544A MX385110B (es) | 2014-07-16 | 2015-06-15 | Compuestos de quinoxalina, método para preparar los mismos y uso de los mismos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10745360B2 (es) |
| EP (1) | EP3169670B1 (es) |
| JP (1) | JP6826526B6 (es) |
| KR (1) | KR102433758B1 (es) |
| CN (2) | CN117088821A (es) |
| AU (1) | AU2015290176B2 (es) |
| CA (1) | CA2954879C (es) |
| MX (1) | MX385110B (es) |
| NZ (1) | NZ728498A (es) |
| SG (1) | SG11201700276QA (es) |
| TW (1) | TWI565698B (es) |
| WO (1) | WO2016010662A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3684772B1 (en) * | 2017-09-20 | 2023-12-06 | ABM Therapeutics Corporation | Cyclic iminopyrimidine derivatives as kinase inhibitors |
| TW202313628A (zh) | 2021-06-08 | 2023-04-01 | 美商Ｃ４醫藥公司 | 用於降解突變braf之治療劑 |
| CN114605391B (zh) * | 2022-02-21 | 2024-01-26 | 广州六顺生物科技股份有限公司 | 喹喔啉类衍生物及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060010568A1 (en) * | 2004-01-27 | 2006-01-19 | Wiles William A | Helmet sweat band |
| WO2006040568A1 (en) * | 2004-10-15 | 2006-04-20 | Astrazeneca Ab | Quinoxalines as b raf inhibitors |
| CA2658725A1 (en) * | 2006-08-16 | 2008-02-21 | Exelixis, Inc. | Using pi3k and mek modulators in treatments of cancer |
| MX2010000617A (es) * | 2007-07-17 | 2010-05-17 | Plexxikon Inc | Compuestos y metodos para modulacion de cinasa, e indicaciones de estos. |
| WO2012008492A1 (ja) * | 2010-07-13 | 2012-01-19 | 株式会社テレシステムズ | Ｘ線断層像撮影装置 |
| WO2012118492A1 (en) * | 2011-03-01 | 2012-09-07 | Array Biopharma Inc. | Heterocyclic sulfonamides as raf inhibitors |
| JP6002223B2 (ja) * | 2011-08-26 | 2016-10-05 | ニューファーマ， インコーポレイテッド | 特定の化学的実体、組成物、および方法 |
| WO2013043935A1 (en) * | 2011-09-21 | 2013-03-28 | Neupharma, Inc. | Certain chemical entites, compositions, and methods |
-
2015
- 2015-06-15 WO PCT/US2015/035822 patent/WO2016010662A1/en not_active Ceased
- 2015-06-15 EP EP15822821.3A patent/EP3169670B1/en active Active
- 2015-06-15 CN CN202310977136.7A patent/CN117088821A/zh active Pending
- 2015-06-15 CN CN201580038477.1A patent/CN106536488A/zh active Pending
- 2015-06-15 MX MX2017000544A patent/MX385110B/es unknown
- 2015-06-15 JP JP2017502707A patent/JP6826526B6/ja active Active
- 2015-06-15 SG SG11201700276QA patent/SG11201700276QA/en unknown
- 2015-06-15 NZ NZ728498A patent/NZ728498A/en unknown
- 2015-06-15 CA CA2954879A patent/CA2954879C/en active Active
- 2015-06-15 US US15/326,490 patent/US10745360B2/en active Active
- 2015-06-15 AU AU2015290176A patent/AU2015290176B2/en active Active
- 2015-06-15 KR KR1020177002931A patent/KR102433758B1/ko active Active
- 2015-06-16 TW TW104119488A patent/TWI565698B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016010662A1 (en) | 2016-01-21 |
| AU2015290176B2 (en) | 2019-10-31 |
| JP2017521449A (ja) | 2017-08-03 |
| SG11201700276QA (en) | 2017-02-27 |
| TWI565698B (zh) | 2017-01-11 |
| NZ728498A (en) | 2022-07-01 |
| AU2015290176A1 (en) | 2017-02-16 |
| CN106536488A (zh) | 2017-03-22 |
| EP3169670A4 (en) | 2017-05-24 |
| US10745360B2 (en) | 2020-08-18 |
| KR20170030550A (ko) | 2017-03-17 |
| JP6826526B2 (ja) | 2021-02-03 |
| CA2954879C (en) | 2022-09-06 |
| EP3169670B1 (en) | 2021-10-20 |
| TW201609673A (zh) | 2016-03-16 |
| CN117088821A (zh) | 2023-11-21 |
| MX385110B (es) | 2025-03-11 |
| US20180208561A1 (en) | 2018-07-26 |
| JP6826526B6 (ja) | 2021-03-31 |
| CA2954879A1 (en) | 2016-01-21 |
| KR102433758B1 (ko) | 2022-08-19 |
| WO2016010662A9 (en) | 2016-08-25 |
| EP3169670A1 (en) | 2017-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016015236A2 (pt) | inibidores de serina/treonina quinase | |
| CU24605B1 (es) | Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2 | |
| MX2022008085A (es) | Moleculas peque?as contra cereblon para mejorar la funcion efectora de los linfocitos t. | |
| CO6720985A2 (es) | Método y dispositivo de separaciónde solidos/fluidos para tratamiento de biomasa que incluye separación de sólidos /fluidos | |
| EP4218832A3 (en) | Methods and compositions for 18f-radiolabeling of the fibronectin type (iii) domain | |
| MX2016014248A (es) | Compuestos polifluorados que actuan como inhibidores de la tirosina cinasa de bruton. | |
| CL2018000596A1 (es) | Nuevos compuestos bicíclicos como inhibidores de la atx | |
| ECSP16071151A (es) | Inhibidores de dihidropirrolopiridina de ror-gamma | |
| ECSP10010510A (es) | Compuestos del inhibidor de raf y métodos de uso de los mismos | |
| MX2020001757A (es) | Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. | |
| CL2015002194A1 (es) | Inhbidores de erk y sus usos | |
| MX381417B (es) | Inhibidores de glucosidasa. | |
| EA201490859A1 (ru) | Алкилированные соединения пиперазина в качестве ингибиторов тирозинкиназы брутона | |
| CL2016002148A1 (es) | Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos. | |
| BR112017009806A2 (pt) | sistema e método para gerar informações de nível de estresse e de nível de resiliência de estresse para um indivíduo | |
| DOP2016000140A (es) | Inhibidores de syk | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| UY35821A (es) | Compuesto heterocíclico | |
| CL2016000238A1 (es) | Polimorfo de los inhibidores de la syk | |
| AR102981A1 (es) | Inhibidores de la necrosis celular y métodos de preparación de los mismos | |
| MX382261B (es) | Derivados heterociclicos y uso de los mismos. | |
| DOP2017000289A (es) | Moduladores de receptor nuclear | |
| CL2017000819A1 (es) | Métodos para separar diastereoisoméros de fosfato | |
| ECSP17010481A (es) | Novedosas pirimidinas 2,5-sustituidas | |
| CO2019012125A2 (es) | Inhibidores ip6k |